The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative review

Detalhes bibliográficos
Autor(a) principal: Lopes, Lucas Alonso
Data de Publicação: 2022
Outros Autores: De-Carli, Bruno Paes, Moura, Caio Silva, Manzi, Agatha [UNESP]
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.14450/2318-9312.v34.e1.a2022.pp25-33
http://hdl.handle.net/11449/240890
Resumo: The use of Cannabis sativa for medicinal purposes is a very controversial subject in Brazil, so it is necessary to delve deeper into the theme to elucidate the main questions and possible benefits. Epilepsy is a disease that causes neurological changes, such as epileptic seizures, dysphagia and convulsions. It can lead to cognitive and psychological damage and comorbidities, worsening the patient's quality of life. In this study an integrative review was carried out about the different types of C. sativa cannabinoids and their use for treating epilepsy. The data were obtained from research articles published in periodicals between 1963 and 2020. Special attention was given to different metabolites, such as cannabidiol (CBD). General aspects of epilepsy, phytocannabinoid use in refractory cases and clinical and pre-clinical trials were addressed in this review, emphasizing their biological effects. As a future target for treating epilepsy, the therapeutic use of CBD in neurology shows promising results in cases where the conventional medication has no effect. A contribution of research on other phytocannabinoids and their interrelationship is essential to advance the treatment of epilepsy and other pathologies.
id UNSP_06dadeda90a482e7163975aea849e6bd
oai_identifier_str oai:repositorio.unesp.br:11449/240890
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative reviewO uso de canabinoides de Cannabis sativa L. no tratamento da epilepsia: uma revisão integrativaCannabidiolDelta(9)-THCEpileptic syndromeNeurological disordersSeizuresThe use of Cannabis sativa for medicinal purposes is a very controversial subject in Brazil, so it is necessary to delve deeper into the theme to elucidate the main questions and possible benefits. Epilepsy is a disease that causes neurological changes, such as epileptic seizures, dysphagia and convulsions. It can lead to cognitive and psychological damage and comorbidities, worsening the patient's quality of life. In this study an integrative review was carried out about the different types of C. sativa cannabinoids and their use for treating epilepsy. The data were obtained from research articles published in periodicals between 1963 and 2020. Special attention was given to different metabolites, such as cannabidiol (CBD). General aspects of epilepsy, phytocannabinoid use in refractory cases and clinical and pre-clinical trials were addressed in this review, emphasizing their biological effects. As a future target for treating epilepsy, the therapeutic use of CBD in neurology shows promising results in cases where the conventional medication has no effect. A contribution of research on other phytocannabinoids and their interrelationship is essential to advance the treatment of epilepsy and other pathologies.Universidade Paulista (UNIP), Avenida Francisco Manoel s/n, bairro Vila Matias, SPInstituto de Biociências Universidade Estadual Paulista (UNESP), Campus do Litoral Paulista. Praça Infante Dom Henrique, s/n, bairro Parque Bitaru, PSInstituto de Biociências Universidade Estadual Paulista (UNESP), Campus do Litoral Paulista. Praça Infante Dom Henrique, s/n, bairro Parque Bitaru, PSUniversidade Paulista (UNIP)Universidade Estadual Paulista (UNESP)Lopes, Lucas AlonsoDe-Carli, Bruno PaesMoura, Caio SilvaManzi, Agatha [UNESP]2023-03-01T20:37:19Z2023-03-01T20:37:19Z2022-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article25-33http://dx.doi.org/10.14450/2318-9312.v34.e1.a2022.pp25-33Infarma - Pharmaceutical Sciences, v. 34, n. 1, p. 25-33, 2022.2318-93120104-0219http://hdl.handle.net/11449/24089010.14450/2318-9312.v34.e1.a2022.pp25-332-s2.0-85128930530Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPporInfarma - Pharmaceutical Sciencesinfo:eu-repo/semantics/openAccess2023-03-01T20:37:19Zoai:repositorio.unesp.br:11449/240890Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T19:25:24.438713Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative review
O uso de canabinoides de Cannabis sativa L. no tratamento da epilepsia: uma revisão integrativa
title The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative review
spellingShingle The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative review
Lopes, Lucas Alonso
Cannabidiol
Delta(9)-THC
Epileptic syndrome
Neurological disorders
Seizures
title_short The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative review
title_full The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative review
title_fullStr The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative review
title_full_unstemmed The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative review
title_sort The use of Cannabis sativa L. cannabinoids in the treatment of epilepsy: a narrative review
author Lopes, Lucas Alonso
author_facet Lopes, Lucas Alonso
De-Carli, Bruno Paes
Moura, Caio Silva
Manzi, Agatha [UNESP]
author_role author
author2 De-Carli, Bruno Paes
Moura, Caio Silva
Manzi, Agatha [UNESP]
author2_role author
author
author
dc.contributor.none.fl_str_mv Universidade Paulista (UNIP)
Universidade Estadual Paulista (UNESP)
dc.contributor.author.fl_str_mv Lopes, Lucas Alonso
De-Carli, Bruno Paes
Moura, Caio Silva
Manzi, Agatha [UNESP]
dc.subject.por.fl_str_mv Cannabidiol
Delta(9)-THC
Epileptic syndrome
Neurological disorders
Seizures
topic Cannabidiol
Delta(9)-THC
Epileptic syndrome
Neurological disorders
Seizures
description The use of Cannabis sativa for medicinal purposes is a very controversial subject in Brazil, so it is necessary to delve deeper into the theme to elucidate the main questions and possible benefits. Epilepsy is a disease that causes neurological changes, such as epileptic seizures, dysphagia and convulsions. It can lead to cognitive and psychological damage and comorbidities, worsening the patient's quality of life. In this study an integrative review was carried out about the different types of C. sativa cannabinoids and their use for treating epilepsy. The data were obtained from research articles published in periodicals between 1963 and 2020. Special attention was given to different metabolites, such as cannabidiol (CBD). General aspects of epilepsy, phytocannabinoid use in refractory cases and clinical and pre-clinical trials were addressed in this review, emphasizing their biological effects. As a future target for treating epilepsy, the therapeutic use of CBD in neurology shows promising results in cases where the conventional medication has no effect. A contribution of research on other phytocannabinoids and their interrelationship is essential to advance the treatment of epilepsy and other pathologies.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-01
2023-03-01T20:37:19Z
2023-03-01T20:37:19Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.14450/2318-9312.v34.e1.a2022.pp25-33
Infarma - Pharmaceutical Sciences, v. 34, n. 1, p. 25-33, 2022.
2318-9312
0104-0219
http://hdl.handle.net/11449/240890
10.14450/2318-9312.v34.e1.a2022.pp25-33
2-s2.0-85128930530
url http://dx.doi.org/10.14450/2318-9312.v34.e1.a2022.pp25-33
http://hdl.handle.net/11449/240890
identifier_str_mv Infarma - Pharmaceutical Sciences, v. 34, n. 1, p. 25-33, 2022.
2318-9312
0104-0219
10.14450/2318-9312.v34.e1.a2022.pp25-33
2-s2.0-85128930530
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Infarma - Pharmaceutical Sciences
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 25-33
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808129065108897792

Registros relacionados